UC Davis to develop center for AIDS research to address emerging aids epidemic in north-central California

November 13, 2001

(SACRAMENTO, Calif.) -- The human immunodeficiency virus is increasingly touching the medically underserved and vulnerable in the North-Central Valley, where information about prevention and access to care is poor. But a new Center for AIDS Research is being developed at UC Davis to break the cycle of infection and to bring the benefits of research to residents of these rural communities.

"The whole picture of AIDS and HIV infection in California is shifting," said Thomas Evans, chief of the Division of Infectious Diseases at UC Davis School of Medicine and Medical Center. "Traditionally focused in communities along the Pacific Coast, infection is now moving inland to agricultural centers all along Interstate Highway 5. We need to investigate these new patterns of infection and develop strategies to prevent the spread of AIDS."

With a $2.25 million grant from the National Institutes of Health, Evans is leading the effort to develop the North-Central California Center for AIDS Research to address all aspects of HIV infection, from the laboratory bench to community outreach.

The new center builds on the clinical expertise and successful outreach efforts of several groups of UC Davis physicians in the Division of Infectious Diseases; at the Center for Agricultural Research; and at the Center for AIDS Research, Education and Services (CARES), a free-standing clinic that provides a coordinated response to the Sacramento area's exploding HIV/AIDS epidemic.

It also includes internationally renowned groups of basic and preclinical scientists throughout the UC Davis campus. Experts include researchers from the Center for Comparative Medicine, School of Medicine, School of Veterinary Medicine, and the California Regional Primate Research Center, as well as at the California Department of Health Services and the University of California, Berkeley. Pioneering studies conducted over the past 20 years by individuals at these laboratories have significantly contributed to the understanding of HIV infection, transmission, drug resistance, vaccine development and immune system restoration.

"Our goal is to harness the tremendous strength of these individual programs and direct our collective efforts to outreach and translational research," said Satya Dandekar, professor of infectious diseases at UC Davis and co-principal investigator of the grant. "We aim to work with physicians in the community to meet the challenges of the emerging AIDS epidemic, develop effective strategies that prevent primary HIV infection, and bring early anti-retroviral therapies to agricultural workers and other at-risk populations in rural California."

The new center at UC Davis aims to make it easier for patients, practicing physicians and public health workers to have closer links with HIV experts and leading-edge treatments. At the same time, it will foster communication and interaction between basic researchers and clinicians, which will help advance knowledge of HIV, as well as the prevention and treatment of AIDS in these communities. "UC Davis researchers have developed some new and promising treatment strategies, which we plan to develop into phase 1 clinical trials," said Evans. "Clinicians will also be asking researchers to answer some of the basic questions underlying poor outcomes in current HIV treatments. "

At the HIV-1 program at San Joaquin General Hospital, for example, infectious diseases specialist Charles Krasner and internist Rod Felber treat about 300 patients each year. Unlike treatment centers in Los Angeles and San Francisco, much of their patient population is geographically isolated, poor, multi-ethnic, and non-English speaking. Many are migrant workers and methamphetamine users who are already in an advanced stage of the disease when they first visit the clinic. These patients need special care to comply with treatments and new educational approaches to effectively stop the spread of HIV.

Evans plans to tap the expertise of the UC Davis's award-winning telemedicine program to bring expert care to any patient within 10 or 20 miles of a hospital in Northern California. Using high-speed data lines that allow real-time videoconferencing, the telemedicine project will make research available to everyone in the region, not just those who can drive to Sacramento.

"We want to include patients from Stockton, Redding, South Lake Tahoe, and similar areas in clinical research and give them opportunities to participate in new drug development," said Neil Flynn, a professor of infectious diseases at UC Davis and founding director of CARES, a leading HIV-treatment center in the region.

In addition to assessing the effectiveness of new HIV therapies, the center will fund studies that focus on the behavioral, social and epidemiologic aspects of HIV infection, as well as address language and cultural issues that allow AIDS to spread in rural, ethnic populations.

"We need to know what patients and their families think," said Krasner. "There are a lot of cultural issues that play a role in educating farm workers and maximizing their ability to comply with therapy. But right now, it's really a black hole in terms of knowing what makes patients follow health guidelines."

The new North-Central Center for AIDS Research will support investigations that address major gaps in current knowledge in the basic sciences as well as behavioral and social aspects of medicine. Improving educational outreach is crucial.
-end-
Copies of all news releases from UC Davis Health System are available on the Web at http://news.ucdmc.ucdavis.edu

University of California - Davis Health System

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.